Kiromic BioPharma, Inc. Common Stock
KRBP
KRBP was delisted on the 13th of September, 2023.
17 hedge funds and large institutions have $200K invested in Kiromic BioPharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 10 closing their positions.
9.99% less ownership
Funds ownership: 13.02% → 3.03% (-10%)
15% less funds holding
Funds holding: 20 → 17 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
88% less capital invested
Capital invested by funds: $1.73M → $200K (-$1.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$41.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$26.2K |
| 3 |
Millennium Management
New York
|
+$16.6K |
| 4 |
VF
Virtu Financial
New York
|
+$13.7K |
| 5 |
Goldman Sachs
New York
|
+$5.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$655K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$256K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$244K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$91K |
| 5 |
LPL Financial
San Diego,
California
|
-$70K |
KRBP Hedge Fund Activity: Q2 2022 in Review
17 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q2 2022, worth a combined $200K — down 88% from $1.73M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KRBP and 7 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $41.5K. The largest seller was Kepos Capital, exiting entirely with an estimated $655K sold.
- 17 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q2 2022, down from 20 in Q1 2022.
- Funds reported $200K of Kiromic BioPharma, Inc. Common Stock stock for Q2 2022, down 88% quarter-over-quarter.
- 7 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q2 2022 and 10 closed out, a net change of -3 holders.
- The largest Kiromic BioPharma, Inc. Common Stock buyer in Q2 2022 was HRT Financial, an estimated $41.5K added.
- The largest Kiromic BioPharma, Inc. Common Stock seller in Q2 2022 was Kepos Capital, an estimated $655K sold.
Based on aggregated 13F filings for Q2 2022.